Zevra Therapeutics

Historical price data

Zevra Therapeutics is a mission-driven, commercial-stage biopharma company focused on rare diseases. Its strategy centers on acquiring and in-licensing promising candidates, then efficiently advancing them through clinical development and regulatory approval using a data-centric approach. The company has successfully transitioned to a commercial entity with two marketed products (MIPLYFFA® and OLPRUVA®) and maintains a late-stage pipeline with significant catalysts, including a Phase 3 trial for celiprolol in VEDS and a filed MAA for arimoclomol in NPC in Europe.

A strategic and regulatory-focused development platform centered on acquiring and in-licensing clinical-stage candidates for rare diseases, then advancing them through efficient, data-driven clinical trials and crafting compelling regulatory narratives for approval.